Home / Business and Economy / Merck Strikes $2.13B Cancer Deal with China Firm
Merck Strikes $2.13B Cancer Deal with China Firm
28 Sep
Summary
- Merck to pay up to $2.13 billion for cancer treatment rights.
- The deal is with China's SciBrunch Therapeutics.
- This expands Merck's pipeline ahead of Keytruda patent expirations.
Merck has announced a significant global licensing agreement with SciBrunch Therapeutics of China, involving an initial payment of up to $2.13 billion. This collaboration grants Merck the rights to develop, manufacture, and commercialize an experimental cancer treatment. This strategic initiative is part of Merck's broader effort to strengthen its cancer drug pipeline.
The company is actively seeking to broaden its portfolio as its top-selling immunotherapy, Keytruda, faces patent expirations later this decade. The deal with SciBrunch Therapeutics highlights Merck's commitment to innovation and securing future revenue streams in the competitive oncology market.
